The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...
The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for ...
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...
The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, ...
Alison has more than 35 years of broad experience delivering clinical trials to sponsors with a patient centric mindset.
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast. Boehringer Ingelheim reported this week that its phase 3 Fibroneer-IPF trial had met ...
One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal ...
uMotif, a fast-growing company in the clinical research technology sector, has taken a significant step in expanding its platform with the acquisition of ClinOne, a provider of site platform solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback